EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs

Erminia Ridolo, Alessandro Barone, Martina Ottoni, Silvia Peveri, Marcello Montagni, Francesca Nicoletta

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25031702 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Erminia Ridolo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Biological Products, Enteritis, Eosinophilia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others. Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisBiological ProductsEnteritisEosinophiliaGastritisHumansBiological TherapyBiological Factors

Stichwörter der Autor:innen

benralizumabbiological drugscendakimabdupilumabeosinophilic esophagitislirentelimab mepolizumabmonoclonal antibodiesreslizumabtezepelumab

Substanzen

Biological ProductsBiological Factors

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
  • Departmental Unit of Allergology, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.

Zitieren

APA

Ridolo, E., Barone, A., Ottoni, M., Peveri, S., Montagni, M., & Nicoletta, F. (2024). The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031702

Vancouver

Ridolo E, Barone A, Ottoni M, Peveri S, Montagni M, Nicoletta F. The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031702

BibTeX
@article{Ridolo2024,
  author = {Ridolo, Erminia and Barone, Alessandro and Ottoni, Martina and Peveri, Silvia and Montagni, Marcello and Nicoletta, Francesca},
  title = {The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25031702}
}
Kostenlos starten →